Table 3.
Cohort Host and Viral Risk Factors, According to Duration of Pretreatment Abstinence
| Risk Factors | Duration of Pretreatment Abstinence | Totals (N=241) |
||||
|---|---|---|---|---|---|---|
| Less than 6 Mo. (N = 71) |
6 Mo. to 2 Yrs. (N=31) |
2 to 10 Yrs. (N=62) |
Over 10 Yrs. (N=77) |
P* | ||
| Age (Mean ± SD) | 48.1 (8.6) | 48.1 (7.3) | 48.2 (7.5) | 51.8 (6.1) | 49.9 (7.2) | .005 |
| Gender (% Male) | 66.2% | 83.9% | 61.3% | 53.2% | 63.1% | .025 |
| Race/Ethnicity (% non-Hispanic White) | 84.5% | 87.1% | 75.8% | 77.9% | 80.5% | NS |
| Pretreatment Viral Load (% ≥ 600,000 IU/ml) | 56.3% | 51.6% | 50.8% | 59.7% | 55.4% | NS |
| Genotype (% 1, 4 or 6) | 57.7% | 48.4% | 61.7% | 49.4% | 54.8% | NS |
| Advanced Fibrosis (% Positive) (N=197) | 35.3% | 32.0% | 34.6% | 32.8% | 33.9% | NS |
| Failed to meet 80-80-80 Criteria | 2.9% | 6.7% | 8.3% | 2.6% | 4.7% | NS |
| Treatment Discontinuation (Overall %) | 11.4% | 12.9% | 8.3% | 20.8% | 13.9% | NS |
| For Adverse Events (%) | 8.6% | 12.9% | 6.7% | 15.6% | 10.9% | NS |
| For Non-Compliance (%) | 2.9% | 0% | 1.7% | 3.9% | 2.5% | NS |
| For Unrelated Illness (%) | 0% | 0% | 0%% | 1.3% | 0.4% | NS |
*
The probability of significantly different ages related to pretreatment alcohol intake is based on analysis of variance; elsewhere significance levels are based on 2-sided χ2 tests for categorical variables.